Home  |   About  |   Theory  |   Tutorials  |   FAQ  |   Bahar Lab  |   Statistics


Network of interactions between drugs (red spheres) and targets (blue spheres) is displayed above.
The red lines are used for the predicted interactions and the thickness of edges indicate the confidence score of predictions.

Data source: DrugBank-all; Query type: target; # of requested predictions: 20; Secondary interactions: no
Input target 1: P17948
No. Gene UniProt ID Protein Name Pathway PDB
1 FLT1 P17948 Vascular endothelial growth factor receptor 1 hsa04010; hsa04014; hsa04015; hsa04066; hsa04151; hsa04510; hsa05202; hsa05323 1FLT; 1QSV; 1QSZ; 1QTY; 1RV6; 2XAC; 3HNG; 4CKV; 4CL7

17 known interactions (drugs) of input target (FLT1): Vascular endothelial growth factor receptor 1
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter
1 Approved;
SmallMoleculeDrug DB09221 Polaprezinc Thumb
2 Investigational SmallMoleculeDrug DB06080 ABT-869 Thumb
3 Approved;
SmallMoleculeDrug DB01268 Sunitinib Thumb
4 Investigational SmallMoleculeDrug DB05932 Denibulin Thumb
5 Investigational SmallMoleculeDrug DB04879 Vatalanib Thumb
6 Approved SmallMoleculeDrug DB08896 Regorafenib Thumb
7 Investigational SmallMoleculeDrug DB05075 TG-100801 Thumb
8 Approved;
SmallMoleculeDrug DB12010 Fostamatinib Thumb
9 Approved;
SmallMoleculeDrug DB00398 Sorafenib Thumb
10 Approved;
SmallMoleculeDrug DB06626 Axitinib Thumb
11 Approved SmallMoleculeDrug DB06589 Pazopanib Thumb
12 Approved SmallMoleculeDrug DB09079 Nintedanib Thumb
13 Approved BiotechDrug DB10770 Foreskin fibroblast (neonatal) Thumb
14 Approved;
SmallMoleculeDrug DB09078 Lenvatinib Thumb
15 Investigational BiotechDrug DB06101 IMC-1C11 Thumb
16 Investigational SmallMoleculeDrug DB05913 OSI-930 Thumb
17 Experimental SmallMoleculeDrug DB07288 N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Thumb

20 predicted interactions (drugs) of input target (FLT1): Vascular endothelial growth factor receptor 1
No. Group Type Drug ID Drug Name SMILES
⇨ TargetHunter
Image Confidence score
1 Investigational SmallMoleculeDrug DB05014 XL999 Thumb 61.2%
2 Approved;
SmallMoleculeDrug DB01254 Dasatinib Thumb 54.5%
3 Investigational SmallMoleculeDrug DB05146 XL820 Thumb 53.2%
4 Approved;
SmallMoleculeDrug DB08901 Ponatinib Thumb 52.1%
5 Approved;
SmallMoleculeDrug DB06595 Midostaurin Thumb 48.0%
6 Approved SmallMoleculeDrug DB00619 Imatinib Thumb 44.2%
7 Approved BiotechDrug DB10772 Foreskin keratinocyte (neonatal) Thumb 43.7%
8 Approved;
SmallMoleculeDrug DB08875 Cabozantinib Thumb 43.2%
9 Investigational SmallMoleculeDrug DB12742 Amuvatinib Thumb 42.7%
10 Investigational SmallMoleculeDrug DB05984 RAF-265 Thumb 40.0%
11 Approved SmallMoleculeDrug DB06616 Bosutinib Thumb 37.8%
12 Approved;
SmallMoleculeDrug DB00128 L-Aspartic Acid Thumb 35.5%
13 Experimental SmallMoleculeDrug DB08519 N~4~-(3-methyl-1H-indazol-6-yl)-N~2~-(3,4,5-trimethoxyphenyl)pyrimidine-2,4-diamine Thumb 35.2%
14 Experimental SmallMoleculeDrug DB07334 N-[5-(ETHYLSULFONYL)-2-METHOXYPHENYL]-5-[3-(2-PYRIDINYL)PHENYL]-1,3-OXAZOL-2-AMINE Thumb 34.5%
15 Experimental SmallMoleculeDrug DB04727 N-(4-{4-AMINO-6-[4-(METHYLOXY)PHENYL]FURO[2,3-D]PYRIMIDIN-5-YL}PHENYL)-N'-[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]UREA Thumb 34.4%
16 Experimental SmallMoleculeDrug DB01962 Phosphonotyrosine Thumb 34.2%
17 Approved;
SmallMoleculeDrug DB04868 Nilotinib Thumb 34.1%
18 Approved BiotechDrug DB00039 Palifermin Thumb 34.0%
19 Investigational SmallMoleculeDrug DB12874 Quizartinib Thumb 33.9%
20 Approved;
BiotechDrug DB00102 Becaplermin Thumb 33.0%


Reference:  Hongchun Li, Fen Pei, D. Lansing Taylor and Ivet Bahar. (2020) QuartataWeb: Integrated Chemical–Protein-Pathway Mapping for Polypharmacology and Chemogenomics. Bioinformatics 36(12), 3935–3937.


The QuartataWeb server is maintained by the Bahar Lab at the Department of Computational & Systems Biology at the University of Pittsburgh, School of Medicine, and sponsored by the NIH awards P41 GM103712 and P01 DK096990; and by the Li Lab at Research Center for Computer-Aided Drug Discovery at Shenzhen Institutes of Advanced Technology, CAS.

For questions and comments please contact Hongchun Li.